Connect Biopharma Holdings Ltd Earnings: Beat on Revenue Despite EPS Miss

Connect Biopharma Holdings Ltd (CNTB) reported mixed first-quarter 2026 results on May 22, delivering a significant revenue beat while missing earnings expectations by a wide margin.

The company posted an adjusted loss of $2.35 per share, falling short of the $1.54 per share loss that analysts had estimated. This represents a negative earnings surprise of 53.05%, indicating substantially higher losses than anticipated.

Revenue performance told a different story, with Connect Biopharma generating $1.17 million in quarterly revenue compared to analyst estimates of $692,926. The $477,074 revenue beat translated to a positive surprise of 68.85%, nearly doubling Wall Street expectations.

The $0.81 per share earnings miss suggests the biotech company faced higher-than-expected operating expenses or research and development costs during the quarter. Meanwhile, the 68.85% revenue outperformance indicates stronger-than-projected product sales or milestone payments.

This article is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results.

Putting the 53.05% EPS miss in context

For a clinical-stage biotech, a per-share loss missing the consensus estimate by 53% is meaningful but not unusual in absolute terms. The $2.35 reported loss versus the $1.54 expected loss is a gap of $0.81 per share. Because Connect Biopharma is not yet profitable, the consensus EPS figure is itself an estimate of a loss, and small absolute differences in expense timing (a clinical-trial milestone payment, an R&D write-down, or a one-time stock-based comp adjustment) can produce large percentage swings relative to a small denominator. The 53.05% surprise should be read as the company’s realized loss being about 1.5x what analysts had modeled, not as the business being 50% worse than expected across the board.

Why revenue beat while EPS missed

The split between the top-line beat (revenue +68.85% vs estimates) and the bottom-line miss (EPS −53.05% vs estimates) is the key signal in this report. Two things have to be true at the same time: (1) Connect Biopharma brought in meaningfully more cash from product sales, milestone payments, or collaboration revenue than analysts had projected; (2) operating costs grew faster than revenue, so the bottom line moved against expectations. For a biotech, this pattern is often consistent with a milestone payment arriving in the quarter (lifting revenue) while R&D investment in the pipeline was simultaneously accelerated (lifting expenses faster than the milestone). It is not by itself a sign of deteriorating fundamentals, but it does signal that the cost base is heavier than the Street had modeled.

What this means for the next reporting cycle

Going into Q2 2026, three things matter for Connect Biopharma: (1) whether the Q1 revenue outperformance was driven by a one-time milestone or by a recurring stream that can repeat — milestones show up once and then reset, so a Q2 revenue figure closer to consensus would not be a disappointment; (2) whether R&D and operating expenses normalize, in which case EPS should re-converge toward the consensus estimate even if revenue stays around the Q1 level; (3) any updates to the clinical pipeline or partnership announcements that would explain the elevated expense base. For investors, the Q1 result is more useful as a data point on cost structure than on commercial momentum.

How to read the revenue beat side

The 68.85% revenue beat on a $1.17M actual versus $692,926 estimate is a strong percentage figure, but the dollar magnitude is small: the absolute beat is about $477K. On a single line item that size, a milestone payment from a collaboration partner, a small licensing event, or timing of a product shipment can move the result by this much. The headline “revenue beat” framing is accurate, but the underlying commercial signal is modest at this revenue scale. For larger biotechs, a 68.85% beat would imply major commercial momentum; for a company at this revenue level, the headline should be paired with the caveat that the absolute beat is small enough to be driven by a single discrete event.